MTOR and myeloproliferative neoplasm: A dual PI3K/mTOR inhibitor, BEZ235 when combined with ruxolitinib was more efficacious in suppressing proliferation and inducing apoptosis in MPN model cells and primary CD34+ MF cells than either of the inhibitors alone [88,89].